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Abstract
Background: Zbtb7A is a proto-oncogenic transcriptional regulator that plays an important role
in adipogenesis, osteogenesis and oncogenesis, but little is known about the regulation of Zbtb7A
gene expression which is of importance in the function uncovering of this gene.
Finding: Here, a 5'-flanking region of the human Zbtb7A gene was cloned and characterized. It
was found that the GC box within Zbtb7A promoter is necessary for the promoter activity.
Furthermore, we identified that Sp1 acts as an activator in the regulation of Zbtb7A promoter
activity and the physical interaction between Sp1 and GC box is responsible for the activation of
Zbtb7A gene promoter.
Conclusion: Our results confirmed that Sp1 upregulates Zbtb7A gene expression via direct
binding to GC box within the promoter.
Background
Zbtb7A (FBI-1/Pokemon), an oncogene, is involved in
adipogenesis, osteogenesis and oncogenesis. Zbtb7A con-
tains a POZ/BTB domain at the N-terminus and four
Krüppel-type C2H2 zinc fingers at C-terminus [1]. POZ/
BTB domain mediates homodimerization and het-
erodimerization, and recruitment of corepressors and
HDAC complexes, whereas the C2H2 zinc fingers mediate
specific DNA recognition and binding [2,3].
Zbtb7A was originally identified as a protein that binds
specifically to a HIV type I promoter element [3] and can
physically interact with other POK family members such
as BCL-6 [4]. Zbtb7A has pleiotropic functions such as
repression of genes transcription of ADH5/FDH [5], Rb
[6], FANS [7], CyclinA gene and E2F4[8], NF-KB trans-
activation[9], playing important role in adipogenesis[10],
and osteoclastogenesis [11]. Zbtb7A is also a repressor of
the ARF tumor suppressor gene (p19Arf in the mouse, and
p14ARF in humans) that in turn lowers the expression of
another tumor suppressor p53 gene, and is a central regu-
lator in oncogenesis[1]. Zbtb7A gene amplification is a
relatively frequent event and leads to the over expression
of this gene in non-small cell lung cancer[12]. Recently it
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was reported that proto-oncogene Zbtb7A and SREBP-1
synergistically activate transcription of fatty acid synthase
gene(FASN)[7].
The mechanisms of Zbtb7A gene expression regulation is
of importance for understanding the precise roles of
Zbtb7A in physiological and pathological processes. To
date little is known about the transcriptional regulation of
the Zbtb7A gene.
To better understand the molecular mechanism regulating
expression of the Zbtb7A gene in humans, 5'-upstream
region of Zbtb7A gene was cloned and analyzed. We con-
firmed that the proximal 1000 bp upstream of the transla-
tion start site mediates most of the basal activity and
contains two Sp1 binding sites, and we for the first time
provide evidence that Sp1 enhances the transcription of
Zbtb7Agene through direct binding to GC box of the pro-
moter.
Methods
Cell line and cell culture
Human liver cancer HepG-2 cells and human embryo kid-
ney 293-T cells (American TypeCulture Collection, Man-
assas, VA) were cultured under DMEM medium
containing 10% fetal bovine serum(Hyclone, USA), L-
glutamine(2 mM), streptomycin(0.1 mg/ml) and penicil-
lin(100 U/ml) at 37°C in a humidified incubator sup-
plied with 5% CO2.
Plasmids preparations
Various 5'-3' deletion constructs of pokemon, 4000 bp,
2000 bp, 1000 bp, and 500 bp DNA fragment relative to
a putative transcriptional start site, were generated from
HepG-2 cells. For construction of the putative Zbtb7A
promoter deletion constructs, the reverse primer for PCR
is 5'-GACAAGCTTCTTCCGCGCCGAGACC-3', and the
forward primers were follow:5'-GTAAGATCTGAG-
GAACGGCCCAGCAG-3'(4000 bp),5'-GCTAGATCTG-
TAGCTGGGATTACAGGCACG-3'(2000 bp),
AAATTGAGGCTGGGG-3'(1000 bp),5'-GCTAGATCT-
TCATGCCATTCTCCTGCCTC-3'(500 bp). PCR-amplified
products were digested with enzymes Bglα and Hindβ,
and cloned into the corresponding sites of the pGl4.10-
basic Firely Luciferase expression plasmid (Promega) to
generate the plasmids pLuc-4000, pLuc-2000, pLuc-1000,
pLuc-500 respectively. The internal control pRL-TK
Renilla Luciferase vector was purchased from Promega
Corp. The Sp1 expression construct was generated by
inserting a cDNA fragment obtained by reverse transcrip-
tion PCR from HepG-2cell into pcDNA3.1 (-) vector at the
HindIII and EcoRI sites. The PCR oligonucleotide primer
pair used for the Sp1 cDNA amplification is as follow: 5'-
GAAGAATTCCATGAGCGACCAAGATCAC-3' and reverse
5'-GAAAAGCTTCTCTTGGACCCATGCTAC-3'.
Site directed mutagenesis
Sp1 putative recognition sites mutation of
Zbtb7Apromoter were obtained by preparing the
pLuc638m and pLuc969m constructs, using mutated
primers within GC-boxes. The plasmids with mutation
was generated by using site-directed mutagenesis system
(Promega) according to the protocol recommended by
manufacture and pLuc1000 construct was used as a tem-
plate. The oligonucleotides used for mutagenesis (muta-
tions indicated with inclined form and bold letters) are
following: pLuc638m, 5'-AATGATCCAAAAAAAACT-
GCCTCCCAAG-3'; pLuc969m, 5'- CCCATCTGTA-
CACAAAAAAAACCAGCTGTC-3'.
DNA sequencing was performed to confirm that the
sequence of the PCR products were correct as compared
with the Zbtb7Apromoter published in the Human
Genome database.
Transient Transfections, Luciferase Assay
1 × 105 293 T and HepG-2 cells were seeded respectively
into 24 wells, and 2 μl of Lipofectamine-2000(Invitrogen,
CA, USA) was used for plasmids transfection. At 48 h After
transfection, the cells were harvested, lysed, and luciferase
activities were measured in triplicate using Dual Luci-
ferase™ Reporter Assay System (Promega, Wallisellen,
Switzerland).
RT-PCR
Total RNA was prepared from HepG-2 cells using TRIZOL
reagent (Invitrogen, CA), and cDNA was synthesized
using a reverse transcription synthesis system (TOYOBO,
Japan), according to the manufacture's recommendations.
Oligonucleotide primers used for PCR are as follow: poke-
mon, forward, 5'- GAAGCCCTACGAGTGCAACATC-3',
reverse 5'- GTGGTTCTTCAGGTCGTAGTTGTG-3'; Sp1,
forward: CATGAGCGAC CAAGATCAC, reverse: CTCTT-
GGACCCATGCTAC; GAPDH, forward: 5'- CAACGTGT-
CAGTGGTGGACCTG-3', reverse: 5'-
TTACTCCTTGGAGGCCATGTGG-3'.
Chromatin immunoprecipitation (ChIP) Assay
ChIP Assay was carried out to analyze the physical interac-
tion between Sp1 and Zbtb7Apromoter in the HepG-2
cells. Formaldehyde was added at 1% to the culture media
for 10 min at 37°C to cross-link protein to DNA. Cells
were washed twice with ice-cold 1 × PBS, scraped, and
resuspended in ChIP sonication buffer (1% Triton-100,
0.1% Deoxycholate, 50 mM Tris 8.1, 150 mM NaCl, 5 mM
EDTA) containing protease inhibitors. The cells were son-
icated to shear DNA to lengths between 2000 bp to 500
bp. The sonicated supernatant was diluted with ChIP dilu-
tion buffer, and incubated with antibody against
Sp1(Abcam) overnight at 4°C with rotation. The chroma-
tin-antibody complexes were collected by Dynabeads pro-BMC Research Notes 2009, 2:175 http://www.biomedcentral.com/1756-0500/2/175
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tein G (Invitrogen). After wash with pH 5.0 TE beffer (10
mM Tris, 1 mM EDTA) for three times, the pellet was dis-
solved with pH 3.0 TE buffer. After precipitation with eth-
anol, the pellets were resuspended and treated with
proteinase K. The supernatant was extracted with satu-
rated NaCl and precipitated with 2-propanol to recover
DNA. The primers for ChIP PCR were designed to amplify
two putative Sp1 binding sites in Zbtb7Acore promoter
sequence: primer forward, 5'- GGGAAACTGAGGCT-
GATGG-3', reverse, 5'- TCAGGTGTCCCACTCCCAAC-3'
for-1003 bp to -925 bp amplification, and primers for-
ward, 5'- ACTGCACTTGGGAACAGC-3', reverse, 5'-
GGCAACAGAGCAAGACTC-3' for -774 bp to -584 bp
amplification.
Results
Cloning and characterization of the 5' regulatory region of 
Zbtb7Agene
To identify potential cis-acting elements required for basal
Zbtb7Aactivity, we cloned a 4000 bp of DNA fragment
from -4000 to +1, relative to a putative transcriptional
start site from HePG-2 cells. To determine the probable
promoter activity region of the Zbtb7Agene, we generated
a series of 5'-3' deleted luciferase reporter constructs, con-
taining 4000, 2000, 1000, and 500 bp fragments of
Zbtb7Apromoters (Fig. 1A). Functional analysis of those
constructs showed that a proximal promoter (-1000/+1)
maintains high level of basal activity in both 293 T and
HePG2 cells (Fig 1B and Fig 1C), which suggested that it
would contain some important cis-acting elements.
We made use of TFSEARCH program http://www.cbrc.jp/
research/db/TFSEARCH.html to search for potential cis-
elements in the 1000 bp Zbtb7Apromoter, and found two
putative Sp1 binding sites: SpA(-641~636-) and SpB(-
972~-967) as shown in Fig 2A. To determined whether
both putative elements were responsible for basal activity
of the Zbtb7Agene, we mutated those two GC-boxes (also
Sp1 binding site)[13]. As shown in Fig 2B, the mutation
of GGGCGG to AAAAAA of SpA and SpB binding sites
resulted in a 6.3-fold and 14.6-folds decrease of luciferase
activity in HepG2 cells and 5.6-folds and 7.2 folds
Deletion and mutation analysis of the Zbtb7Acore promoter activity Figure 1
Deletion and mutation analysis of the Zbtb7Acore promoter activity. A, schematic representation of 
Zbtb7Apromoter luciferase report plasmids: pLuc-4000, pLuc-2000, pLuc-1000, pLuc-500, containing a series of 5'-3'deleted 
promoters; B, C, HepG-2 and 293 T cells were transient tranfected with 0.8 ug of either Zbtb7Apromoter plasmids or control 
plasmid (pGl4.10).BMC Research Notes 2009, 2:175 http://www.biomedcentral.com/1756-0500/2/175
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decrease in 293 T cells respectively. These results revealed
that two GC-boxes binding sites are required for core pro-
moter activity of the Zbtb7Agene.
Sp1 enhances the core promoter activity of Zbtb7A gene
To further understand the role of Sp1 in Zbtb7Agene tran-
scription, we used 293 T and HePG2 cells as cell model for
luciferase reporter assay. Data in Fig. 3A showed that core
promoter activity of the Zbtb7Agene increased with the
elevated amount of Sp1 expression constructs in 293 T
and HePG2 cells, which indicates that basal promoter
activity of Zbtb7Agene could be enhanced by the expres-
sion of Sp1. Whereas the Sp1 increased basal promoter
activity could be abrogated by the mutation of GC boxes
which suggestes that the GGGCGG sequence contributes
to Sp1 induced activation of basal promoter activity of
Zbtb7Agene (Fig. 3A). RT-PCR was used to confirm those
results, and as shown in Fig. 3B, Zbtb mRNA was greatly
elevated by the over expression of Sp1 in 293 T cells.
Sp1 directly binds to the proximal promoter of pokemon
To further investigate the role of the GC-boxes in regulat-
ing the Zbtb7Apromoter activity in response to Sp1, we
performed ChIP analysis to evaluate the binding capacity
of Sp1 to bind Zbtb7Apromoter. Two pairs of primers
were designed corresponding to SpA and SpB sites for the
ChIP PCR. As shown in Fig 4, Sp1 is capable of binding to
SpA site, whereas SpB site dose not show direct physical
interaction with Sp1.
Discussion
Sp1 (specificity protein 1), an important transcription fac-
tor, is ubiquitous expressed and has three C2H2-type zinc
figures as DNA binding domain(DBD) [13-18]. Sp1 bind
Searching for potential cis-elements in the 1000 bp Zbtb7Apromoter Figure 2
Searching for potential cis-elements in the 1000 bp Zbtb7Apromoter. A, The core promoter contains consensus 
sequences for binding transcription factor Sp1(bold and underlined); B, Mutation analysis of the Sp1-binding sites in the 
Zbtb7Apromoter. Two mutants were constructed and used for transient promoter assays.BMC Research Notes 2009, 2:175 http://www.biomedcentral.com/1756-0500/2/175
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Sp1 increased basal promoter activity could be abrogated by the GC boxes mutation Figure 3
Sp1 increased basal promoter activity could be abrogated by the GC boxes mutation. A, Sp1 enhances the core 
promoter activity of Zbtb7Agene. HepG-2 and 293 T cells were transient co-tranfected with either pLuc-1000 and pCDNA3.1, 
or Sp1 and pLuc-10000 or SpAm or SpBm. pGl4.10 was control B, RT-PCR analysis of Zbtb7AmRNA using the total RNA was 
isolated from 293 T cells tranfected Sp1.GAPDH was control. Data for A means for ± SD from three independent experi-
ments, with each experiment carried out in triplicate.
Chromaitin immunoprecipitation (ChIP) assays Figure 4
Chromaitin immunoprecipitation (ChIP) assays. Sheared chromatin from HePG2 cells was immunoprecipitated using 
Sp1 antibody. PCR primers were designed to amplify sequences:-1003 to -925(SpB site) and -774 to -584(SpA site) in the core 
promoter of Zbtb7Agene.BMC Research Notes 2009, 2:175 http://www.biomedcentral.com/1756-0500/2/175
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with higher affinity to GC boxes than to GT boxes or CT
boxes and Sp1 bind to GC-boxes with the consensus
sequence 5'-GGGCGG-3' or 5'-GGCG-3'[19,20]. An
important role of Sp1 in cell growth control and tumori-
genesis was reported recently [21-26]. Many Sp1 targeting
genes, such as CyclinE, Cdk2, E2F1 and c-Myc, are key reg-
ulator of cell proliferation and carcinogenesis [27,28].
Zbtb7A was first identified as a cellular factor binding to a
specific sequence within the human immunodeficiency
virus, type 1 promoter[3]. A serial of reports revealed
important roles of Zbtb7A in human and mouse adipo-
genesis [7], human cancer pathogenesis [1,9] and cell's
determination of B versus T lineage [29]. Zbtb7Afunctions
as an active regulator of genes expression, and several
tumor repressors such as Rb and ARF can be repressed by
Zbtb7A[1]. Although its importance in pathology and
physiology, the Zbtb7Aexpression regulation remains elu-
sive.
The results in the present study identify important cis-ele-
ments located in the proximal Zbtb7Apromoter (-1000-
+1) which are responsible for basal transcriptional activity
of the promoter. Two GC boxes, the core consensus of Sp1
binding site, were identified, and the mutation of Sp-A
and Sp-B leaded to an approximate 80% decrease of the
promoter basal activity respectively in both 293 T and
HePG2 cells, indicating the importance of those sites in
maintaining Zbtb7A promoter basal activity. ChIP analy-
sis revealed that Sp1 could physically interact with Sp-A
site, whereas the site of Sp-B showed no direct interaction
with Sp1. The fail of Sp-B binding with Sp1 may be due to
the involvement of other cofactors in the Sp-B site, since it
was reported that other Sp family protein such as Sp3 also
have high affinity with GC box[23]. Toyoda A et al
revealed that only three of five GC box sequences in
human NADH-cytochrome b5 reductase-encoding gene
(CYTB5R) promoter are Sp1 responsive elements which
suggest Sp1-mediated regulation of gene transcription
occurs in a promoter context-dependent manner[30]. Fur-
thermore, luciferase activity assay showed that the basal
activity of Zbtb7A promoter could be activated by the Sp1
and Sp1 can also up-regulate the transcription of pokmon
mRNA which indicates that Sp1 acts as a positive regulator
in the expression of pokmon gene.
In summary, in this study, we for the first time provide
evidence that Sp1 contributes to the Zbtb7Aexpression
regulation through direct binding to the GC-rich element
within the promoter region.
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